OncoMatch/Clinical Trials/NCT06471205
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Is NCT06471205 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 Monoclonal Antibody for triple-negative breast cancer.
Treatment: BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate with topoisomerase I inhibitor payload
ADC drugs that have received topoisomerase I inhibitors as small molecule toxins
Cannot have received: checkpoint inhibitor
Exception: prior to neoadjuvant/adjuvant chemotherapy
Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy
Cannot have received: immunomodulatory drug
Use of an immunomodulatory drug within 14 days before the first dose of study drug
Cannot have received: palliative radiotherapy
Palliative radiotherapy within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify